Sponsor:
Oruka Therapeutics, Inc.
Code:
NCT07783542
Conditions
Hidradenitis Suppurativa (HS)
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
ORKA-002
Placebo
Brief summary:
Conditions
Hidradenitis Suppurativa (HS)
Study ID
NCT07783542
Start date
Aug 20, 2026
Status verified date
Aug, 2026
Completion date
Sep, 2029
Anticipated
Primary completion date
Oct, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
200 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Induction Period - Arm 1 (ORKA-002)
experimental: Induction Period - Arm 2 (Placebo)
Interventions
ORKA-002
Placebo
Primary outcome measure
Central contacts
Locations
Oruka Therapeutics Investigative Site
Recruiting
Dallas, Texas, United States, 75246
Contacts
Sponsor
Oruka Therapeutics, Inc.
Last update posted
Aug 31, 2026
Last verified
Aug, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Oruka Therapeutics, Inc. on 2026-08-31.